Research Radartracking 1,189 published studies · 293 human · 6 safety signals · 42 clinical trials · 44 cancer pages · updated Jul 2026Open the Research Map →

Intracranial Sarcoma

A plain-English summary of the published research on Intracranial Sarcoma, reviewed and approved by our editors — not a hand-curated clinical overview.

Research summary · reviewed
Educational only: This page is not medical advice. Coordinate decisions with your oncology team.

Reviewed Jun 2026 · OncoForge editorial · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed· last updated Jun 2026

Evidence at a glanceHuman trial / meta-analysisMixed results⚠ Studies disagree
20 published studies that name Intracranial Sarcoma9 human studies approved & graded (trial, observational, or meta-analysis)2 human clinical studies in the Intracranial Sarcoma corpus105 source documents in the Intracranial Sarcoma corpus

last checked June 20, 2026

Why this grade?

Human trial / meta-analysis — Includes human trial or meta-analysis evidence.

Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.

What the guidelines say

NCI PDQESMONCCNASCO

We link the authoritative guidelines rather than reproduce them. Below, the treatments on this page are split into standard care, guideline or regulatory options, supportive care, and studied but not standard so established care is not mixed with experimental or supportive items.

Studied, not standard - investigational
  • idarubicin and arabinocytidine
  • intrathecal chemotherapy
  • radiation
  • proton therapy
  • limited surgery
  • radical resection
  • postoperative whole-brain irradiation
  • external radiotherapy
  • retinoic acid receptor (RAR) signaling activation
  • surgery
  • vincristine
  • dactinomycin
  • cyclophosphamide
  • ifosfamide
  • doxorubicin
  • etoposide
  • VAC regimen (vincristine, dactinomycin, cyclophosphamide)
  • Cobalt-60 external beam radiation therapy
  • whole brain radiation therapy
  • narrow field irradiation
  • chemo-radiation
  • Carboplatin

Read the guidelines

Cancer-specific deep links aren’t curated yet — these search the authoritative sources for Intracranial Sarcoma.

Treatment map: Intracranial Sarcoma

Open as a full page →

Standard care plus every compound studied in the literature (each cited) and graded by evidence, organized by clinical readiness. A category, not a verdict that anything works — confirm anything here with your oncology team.

22
Interventions
0
Standard of care
3
Tested in people
0
Lab / animal
19
Named in lit.
5
Classes
Standard of care (0) Guideline option (0) Tested in people (3) Lab / animal only (0) Named in the literature (19)

Tested in people, by trial phase: phase not reported ×3

Clinical evidence
Preclinical evidence
Standard of care
Guideline option
Tested in people
Lab / animal only
Named in the literature
Surgery & procedures
—
—
—
—
3
Radiotherapy
—
—
—
—
7
Chemotherapy
—
—
3
—
7
Targeted therapy
—
—
—
—
1
Other
—
—
—
—
1

Columns group into clinical evidence (used in, or tested on, people) and preclinical evidence (lab/animal, or only named in the literature). Cell = number of interventions; a dashed cell means none recorded there.

Investigational & adjunct compounds — detail (22)
Named in the literature
idarubicin and arabinocytidineintrathecal chemotherapyradiationproton therapylimited surgeryradical resection· Recurrent or later-linepostoperative whole-brain irradiation· Adjuvant (after surgery)external radiotherapyretinoic acid receptor (RAR) signaling activationsurgeryvincristineoff-labeldactinomycincyclophosphamideoff-labeldoxorubicinoff-labelVAC regimen (vincristine, dactinomycin, cyclophosphamide)Cobalt-60 external beam radiation therapywhole brain radiation therapy· Adjuvant (after surgery)narrow field irradiation· Adjuvant (after surgery)chemo-radiation

"Tested in people" rows show the highest trial phase found in that compound's cited human studies (Phase I–IV; "phase not reported" = a human study with no phase tag). "Studied" = named in the cited literature for this cancer. "FDA ✓" = FDA-approved for this cancer; "off-label" = an FDA-approved drug used outside its approved indications (per openFDA). Not a claim that anything works.

Reported figures

Get cited updates on Intracranial Sarcoma
A monthly email when the research changes — $10/mo. Manage follows
Follow Intracranial Sarcoma

Snapshot

The essentials in ~60 seconds — every line is drawn from the cited sources below.

What it is
Primary intracranial sarcoma, DICER1‑mutant, is a recently described rare pediatric central nervous system tumour defined by characteristic genomic and DNA‑methylation profiles and a partial association with DICER1 mutations. [1][2]
Survival
Prognosis is variable but can be poor for metastatic disease: five‑year survival for metastatic Ewing sarcoma in the CNS is reported as less than 30%, and in one historic series only 1 of 19 patients treated with surgery and postoperative radiotherapy was alive beyond five years. [3][4]
Standard treatment
Treatment is subtype‑specific: intracranial myeloid sarcoma is managed with standard acute myeloid leukemia chemotherapy (2 induction courses with idarubicin and arabinocytidine followed by 4 consolidation courses, often with intrathecal chemotherapy and sometimes radiation), while Ewing and metastatic intracranial sarcomas are treated with multimodality therapy combining surgery, multiagent chemotherapy (for localized Ewing examples include cyclophosphamide, ifosfamide, doxorubicin, dactinomycin, etoposide) and radiation. [5][3]
Key test
DICER1 mutation testing (including germline testing) and DNA methylation profiling are critical at diagnosis for accurate classification and for assessing hereditary tumor predisposition. [1][2][6]
Biggest challenge
The main clinical problems are marked histological variability and diagnostic uncertainty that require upfront molecular and epigenomic profiling, and a lack of faithful preclinical models that hampers development of new therapies. [1][7][6][2]

Ask about Intracranial Sarcoma

Answers come only from the cited sources on this page — with the supporting evidence shown. If the sources here don't cover your question, it will say so. Educational information, not medical advice.

Key numbers & factors

Risk factors

  • ▲ increases riskGermline pathogenic DICER1 variants — Identified in reported cases and significant for diagnosis and hereditary management; same germline mutation reported in a patient and his son. [2][6]
  • ▲ increases riskHistory of organ transplantation / transplant recipient — Transplant recipients have had a much higher than expected incidence of reticulum cell sarcoma of the brain. [4]

Biomarkers

  • DICER1 mutation (somatic and germline)ActionableDiagnostic classification and assessment of hereditary tumor predisposition [1][2][6]
  • EWSR1-FLI1 fusion (t(11;22))ActionableConfirms diagnosis of Ewing sarcoma [3]
  • Loss of H3K27 trimethylation and nuclear TLE1 expression · Immunohistochemical features often seen in DICER1‑mutant intracranial sarcoma [1]
  • TP53, ATRX, KRAS mutations · Additional somatic alterations reported in some DICER1‑mutant cases [2][7]
  • TSC-22 expression loss · Complete lack of expression observed in at least one brain sarcoma sample and linked to a proposed tumor suppressor role [8]

9 sections — tap any heading to expand its cited detail. Key points are above.

OverviewPrimary intracranial sarcomas are rare central nervous system tumors that include a recently described DICER1‑mutant primary intracranial sarcoma with characteristic genomic and DNA‑methylation profiles. Diagnosis is challenging because of marked histopathological variability and heterologous elements; imaging features have been reported for related intracranial sarcomatous lesions such as brain myeloid sarcoma.4 points
  • Primary intracranial sarcoma, DICER1‑mutant, is a recently described central nervous system tumour with specific genomic and DNA‑methylation profiles; primary intracranial sarcoma (PIS) is a rare, pediatric brain tumor that is partially associated with DICER1 mutation. [1][2]
  • Reported histological features of primary intracranial sarcomas include focal spindle‑cell morphology, intracytoplasmic eosinophilic granules, and focal heterologous differentiation, but significant histological variability, lack of differentiation, presence of heterologous elements, and a haphazard pattern of growth create diagnostic challenges. [1][7]
  • In one series of brain myeloid sarcoma, mean lesion size on MRI was 2.0 ± 0.8 cm; most lesions demonstrated restricted diffusion on diffusion‑weighted imaging and showed mild-to-moderate lower perfusion on ASL perfusion imaging. [5]
  • Reticulum cell sarcoma of the brain is a rare neoplasm. [4]
Key biomarkersPathogenic DICER1 variants are a recurring biomarker in primary intracranial sarcoma, with both somatic and germline alterations reported; affected tumors can show characteristic immunohistochemical and molecular features, and DNA methylation profiling may reclassify tumors as DICER1-mutant. Other reported biomarkers in intracranial sarcomas include loss of TSC-22 expression in at least one sample and the EWSR1-FLI1 fusion (t(11, 22)) that characterizes Ewing sarcoma.7 points
  • Sequencing studies of primary intracranial sarcoma have identified pathogenic DICER1 mutations: targeted exome sequencing confirmed pathogenic biallelic DICER1 mutations in all tumours in a reported series, and next-generation/somatic profiling detected specific DICER1 variants (p.E1705V, p.Y1417Ter) in individual cases. [1][7][2]3 sources
  • DICER1-mutant intracranial sarcoma cases have been reported with additional somatic alterations, including mutations in TP53, ATRX, and KRAS. [2][7]
  • Primary intracranial sarcoma, DICER1-mutant tumours often show loss of H3K27 trimethylation and nuclear TLE1 expression by immunohistochemistry. [1]
  • DNA methylation profiling has led to re-evaluation and reclassification of at least one tumor as primary intracranial sarcoma, DICER1-mutant. [6]
  • Complete lack of expression of TSC-22 was observed in at least one sample of brain sarcoma in a series comparing brain tumours and normal brain. [8]
  • Chromosomal translocation t(11, 22) is found in more than 90% of Ewing sarcomas and results in formation of the EWSR1-FLI1 fusion gene; detection of this fusion can be used to confirm a diagnosis of Ewing sarcoma. [3]
Show 1 lab & early-research finding
  • Germline pathogenic variants of DICER1 have been identified in reported cases and are significant for diagnosis and management of hereditary tumor predisposition; in one report the same germline DICER1 mutation was confirmed in both the patient and his son. [2][6]
Biology & pathwaysIntracranial sarcomas show varied cellular composition and ultrastructural features similar to extracerebral sarcomas and have been reported in both humans and dogs. Molecular findings reported in these tumors include decreased TSC-22 mRNA (suggesting a tumor suppressor role), the EWSR1-FLI1 fusion from t(11;22) in Ewing sarcoma, and, in at least one case, a high CSF tumor cell labeling index (>14.4%) associated with a rapid clinical course.5 points
  • Decreased TSC-22 mRNA levels and its antiproliferative role in brain tumours have been interpreted as strongly suggesting a tumor suppressor role for TSC-22. [8]
  • Tumors have been reported to be composed of several cell types, including undifferentiated cells and cells with ultrastructural features of reticulum cells and histiocytes; there appeared to be no significant difference in fine structure between intracranial reticulum cell sarcoma cells and extracerebral forms. [9]
  • In one case, CSF tumor cells had a high labeling index (reported as more than 14.4% for tumor cells) that was consistent with an extremely rapid clinical course. [10]
  • Intracranial sarcomas have been reported in dogs and can show histologic, immunohistochemical, and ultrastructural features consistent with encephalic fibrosarcoma; in a reported canine case, myogenic differentiation suggested by immunohistochemistry could not be confirmed by transmission electron microscopy. [11]
  • The chromosomal translocation t(11, 22) produces the EWSR1-FLI1 fusion gene in most Ewing sarcomas, and the mutation underlying Ewing sarcoma is thought to occur in a gene that regulates cell growth and division, leading to uncontrolled proliferation of cancerous cells. [3]
Standard managementManagement of intracranial sarcomas is subtype- and stage-dependent and commonly uses multimodality approaches including surgery, chemotherapy, and radiation. Specific regimens and recommendations vary by histology—for example, myeloid sarcoma is treated with acute myeloid leukemia–type chemotherapy, while Ewing sarcoma is managed with multiagent chemotherapy and local control measures.8 points
  • Standard chemotherapy for myeloid sarcoma is described as identical to that of acute myeloid leukemia and comprised of 2 courses of induction chemotherapy (idarubicin and arabinocytidine) and 4 courses of consolidation chemotherapy. [5]
  • In a reported series of patients with intracranial myeloid sarcoma, all patients underwent standard induction chemotherapy and intrathecal chemotherapy, and 4 patients also underwent radiation treatment. [5]
  • Early diagnosis of myeloid sarcoma and prompt treatment is associated with improved survival. [5]
  • If possible, limited surgery to remove circumscribed tumors should be done, and extensive resection should be avoided. [4]
  • Postoperative irradiation was recommended to include the whole brain to at least 4500 rads with a boost to residual tumor of 500 to 1000 rads in two to five treatments; although several authors have commented on the tumor's radioresponsiveness, little detail about exact treatment methods has been provided in the literature. [4]
  • In one adult case reclassified as primary intracranial sarcoma, DICER1-mutant, radical resection followed by external radiotherapy resulted in an unusually prolonged relapse-free survival. [6]
  • For metastatic intracranial sarcomas (including metastatic Ewing sarcoma of the brain), multimodality treatment combining surgery, chemotherapy, and radiation is utilized. [3]
  • For localized Ewing sarcoma, multiagent chemotherapy regimens including cyclophosphamide, ifosfamide, doxorubicin, dactinomycin, and etoposide have been reported. [3]
Treatments & compounds studied22 distinct therapeutics and procedures are reported across chemotherapy, radiotherapy, targeted therapy, procedural/device approaches, and other modalities.21 treatments

Chemotherapy

  • idarubicin and arabinocytidine: Standard induction chemotherapy for myeloid sarcoma has been described as comprising idarubicin and arabinocytidine. [5]
  • intrathecal chemotherapy: Intrathecal chemotherapy was administered to all patients in a reported brain myeloid sarcoma series. [5]
  • vincristine: Vincristine (part of VAC) was used in reported systemic chemotherapy regimens for Ewing sarcoma. [3]
  • dactinomycin: Dactinomycin (part of VAC) was used in reported systemic chemotherapy regimens for Ewing sarcoma. [3]
  • cyclophosphamide: Cyclophosphamide (part of VAC) was used in reported systemic chemotherapy regimens for Ewing sarcoma. [3]
  • ifosfamide: Ifosfamide has been included in multiagent chemotherapy regimens for Ewing sarcoma. [3]
  • doxorubicin: Doxorubicin has been included in multiagent chemotherapy regimens for Ewing sarcoma. [3]
  • etoposide: Etoposide has been included in multiagent chemotherapy regimens for Ewing sarcoma. [3]
  • VAC regimen (vincristine, dactinomycin, cyclophosphamide): The VAC chemotherapy regimen (vincristine, dactinomycin, cyclophosphamide) was used for systemic treatment in a reported patient, administered as six cycles. [3]

Targeted therapy

Show 1 lab & early-research entry
  • retinoic acid receptor (RAR) signaling activation: Activation of the retinoic acid receptor (RAR) signaling pathway reduced tumor cell viability in preclinical testing and was identified as a potential therapeutic target for DICER1-mutant PIS. [2]

Radiotherapy

  • radiation: Some patients in a reported series additionally received radiation treatment. [5]
  • proton therapy: Proton therapy centres commonly treat head and neck, brain, sarcoma and pediatric malignancies according to a facility planning report. [12]
  • postoperative whole-brain irradiation: Adjuvant (after surgery)Postoperative whole-brain irradiation to at least 4500 rads with a boost to residual tumor was recommended in a historic series. [4]
  • external radiotherapy: External radiotherapy was used after radical resection in a reported adult DICER1-mutant primary intracranial sarcoma case. [6]
  • Cobalt-60 external beam radiation therapy: External beam radiotherapy (Cobalt-60) was delivered in reported treatment of metastatic brain Ewing sarcoma. [3]
Show 2 lab & early-research entries
  • whole brain radiation therapy: Adjuvant (after surgery)Whole brain radiation therapy was used as part of postoperative management in a reported case (30 Gy). [3]
  • narrow field irradiation: Adjuvant (after surgery)Narrow field irradiation to the involved frontal lobe was used as part of postoperative management in a reported case (15 Gy). [3]

Procedures & devices

  • limited surgery: Limited surgery to remove circumscribed tumors has been recommended when possible. [4]
  • radical resection: Recurrent or later-lineRadical resection followed by external radiotherapy was reported in one adult DICER1-mutant case and was associated with an unusually prolonged relapse-free survival. [6]
  • surgery: Surgery (resection) is used to remove metastatic brain lesions from Ewing sarcoma. [3]

Other

Show 1 lab & early-research entry
  • chemo-radiation: Chemo-radiation was given to a pediatric intracranial high-grade sarcoma patient in a reported case prior to recurrence. [7]
PrognosisPrognosis for intracranial sarcomas varies by subtype, stage, and treatment: some reports document an 80% complete remission rate in a brain myeloid sarcoma series and associate early diagnosis with improved survival, and individual cases describe unusually prolonged relapse-free survival after radical resection and radiotherapy; other series report limited long-term outcomes — for example, only one patient was reported alive and free of disease beyond five years in a 19-patient series, and five-year survival for CNS-metastatic Ewing sarcoma is reported as less than 30%.5 points
  • In a brain myeloid sarcoma series, most lesions (80%) were significantly alleviated after two chemotherapy courses and further improved after four courses; only a few lesions (5%) were residual after six courses. [5]
  • In a series of 19 patients treated with surgery followed by postoperative radiotherapy, only one patient was reported alive and free of disease beyond five years. [4]
  • An adult patient reclassified as having DICER1-mutant primary intracranial sarcoma experienced an unusually prolonged relapse-free survival after radical resection and external radiotherapy. [6]
  • The prognosis of Ewing sarcoma is generally poor for patients with metastatic disease in the CNS, with a five-year survival rate reported as less than 30%. [3]
  • Long-term disease-free survival is reported as possible with adherence to the appropriate therapeutic regimen after gross surgical resection. [3]
Safety & interactions1 point
  • Uncertainties in dose–response risk models can produce uncertainties in lifetime attributable second-cancer risk estimates that are often in excess of 100% for organs. [13]
What we don't know yetKey gaps include diagnostic uncertainty for some intracranial sarcomas that may require molecular or epigenomic methods for precise classification, a shortage of faithful preclinical models that limits therapeutic development, and limited clinical research in related areas such as trials led by cancer nurses and metastatic brain Ewing sarcoma.5 points
  • Significant histological variability and lack of differentiation in some primary intracranial sarcomas complicates diagnosis; epigenomic (DNA methylation) profiling and upfront molecular studies are proposed or considered critical for precise classification. [1][6][7]3 sources
  • A scoping review found that no trials of interventions led or delivered by cancer nurses were conducted in brain, sarcoma, or other rare cancer types. [14]
  • More research on metastatic brain Ewing sarcoma is encouraged to improve understanding of diagnosis and treatment protocols. [3]
  • A lack of faithful preclinical models has hampered the development of novel therapeutic strategies for primary intracranial sarcoma. [2]
  • Preclinical testing identified the retinoic acid receptor (RAR) signaling pathway as a potential therapeutic target for DICER1-mutant primary intracranial sarcoma. [2]
EpidemiologyCentral nervous system (CNS) tumors are the second most common tumors in the pediatric age group and account for 3.5% of overall mortality. Ewing sarcoma is uncommon in children (about 1% of pediatric cancers, with 200-250 new US cases yearly) and metastases to the CNS have been estimated at less than 5% (reported as less than 4.3% in a case report); transplant recipients have shown a much higher than expected incidence of reticulum cell sarcoma of the brain.4 points
  • Central nervous system (CNS) tumors are the second most common in the pediatric age group, accounting for 3.5% of overall mortality. [7]
  • Ewing sarcoma accounts for only about 1% of all pediatric cancers and each year 200-250 new cases are diagnosed in the United States. [3]
  • Patients who have been recipients of transplants have had a much higher than expected incidence of reticulum cell sarcoma of the brain. [4]
Show 1 lab & early-research finding
  • Metastases to the central nervous system from Ewing sarcoma have most recently been estimated to occur in less than 5% of cases, and previous research reported metastatic Ewing sarcoma to the brain parenchyma as less than 4.3% in a case report. [3]

Common questions

What is Intracranial Sarcoma?

Primary intracranial sarcomas are rare central nervous system tumors that include a recently described DICER1‑mutant primary intracranial sarcoma with characteristic genomic and DNA‑methylation profiles. Diagnosis is challenging because of marked histopathological variability and heterologous elements; imaging features have been reported for related intracranial sarcomatous lesions such as brain myeloid sarcoma.

How common is Intracranial Sarcoma?

Central nervous system (CNS) tumors are the second most common tumors in the pediatric age group and account for 3.5% of overall mortality. Ewing sarcoma is uncommon in children (about 1% of pediatric cancers, with 200-250 new US cases yearly) and metastases to the CNS have been estimated at less than 5% (reported as less than 4.3% in a case report); transplant recipients have shown a much higher than expected incidence of reticulum cell sarcoma of the brain.

Which biomarkers are important in Intracranial Sarcoma?

Pathogenic DICER1 variants are a recurring biomarker in primary intracranial sarcoma, with both somatic and germline alterations reported; affected tumors can show characteristic immunohistochemical and molecular features, and DNA methylation profiling may reclassify tumors as DICER1-mutant. Other reported biomarkers in intracranial sarcomas include loss of TSC-22 expression in at least one sample and the EWSR1-FLI1 fusion (t(11, 22)) that characterizes Ewing sarcoma.

What is the biology of Intracranial Sarcoma?

Intracranial sarcomas show varied cellular composition and ultrastructural features similar to extracerebral sarcomas and have been reported in both humans and dogs. Molecular findings reported in these tumors include decreased TSC-22 mRNA (suggesting a tumor suppressor role), the EWSR1-FLI1 fusion from t(11;22) in Ewing sarcoma, and, in at least one case, a high CSF tumor cell labeling index (>14.4%) associated with a rapid clinical course.

How is Intracranial Sarcoma treated?

Management of intracranial sarcomas is subtype- and stage-dependent and commonly uses multimodality approaches including surgery, chemotherapy, and radiation. Specific regimens and recommendations vary by histology—for example, myeloid sarcoma is treated with acute myeloid leukemia–type chemotherapy, while Ewing sarcoma is managed with multiagent chemotherapy and local control measures.

What treatments are studied for Intracranial Sarcoma?

22 distinct therapeutics and procedures are reported across chemotherapy, radiotherapy, targeted therapy, procedural/device approaches, and other modalities.

Sources

Every statement above is drawn from these reviewed sources. This page reports what they describe. Sources last checked June 20, 2026.

  1. Review articleLoss of histone H3 trimethylation on lysine 27 and nuclear expression of transducin-like enhancer 1 in primary intracranial sarcoma, DICER1-mutant · 2021
  2. Case reportPrimary intracranial sarcoma associated with DICER1 mutant: a case report and preclinical investigation · 2025
  3. Case reportBrain Metastasis With a Solitary Lesion Secondary to Knee Joint Ewing Sarcoma: A Case Report · 2023
  4. Review articleReticulum cell sarcoma of the brain. A review of the literature and a study of 19 cases · 1975
  5. Review articleUse of magnetic resonance imaging for diagnosis and after treatment of patients with myeloid sarcoma of the brain · 2017
  6. Case reportPrimary Intracranial Sarcoma, DICER1-Mutant, Diagnosed by DNA Methylation Profiling in an Adult Patient with Germline DICER1 Mutation: A Case Report · 2026
  7. Case reportHistopathologic "Evolution" in Pediatric Primary Intracranial High-Grade Sarcoma - a Key that Unlocked the Correct Diagnosis · 2023
  8. Review articleDownregulation of putative tumor suppressor gene TSC-22 in human brain tumors · 2003
  9. Review articleFine structure of primary reticulum cell sacroma of the brain · 1975
  10. Review article3H-thymidine autoradiography of CSF cells in primary reticulum cell sarcoma of the brain · 1975
  11. Case reportEncephalic fibrosarcoma in a dog · 2026
  12. Review articleProton Therapy Facility Planning From a Clinical and Operational Model · 2015
  13. Review articleAssessment of uncertainties in radiation-induced cancer risk predictions at clinically relevant doses · 2015
  14. Review articleA scoping review of trials of interventions led or delivered by cancer nurses · 2018

What supports this page

The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.

Guideline
1
Meta-analysis
0
Systematic review
0
Randomized trial
0
Clinical trial
4
Observational
0
Case report
64
Review
33
Preclinical
0
Other
3

Living document — last change June 20, 2026: Cancer page updated. 2 recent updates logged.

Pooled evidence across studies

PubMed
  • Imaging finding: 7.5 patients (7–8 across studies) · (regimen unspecified)
    2 studies · 100% agree · consistent38637027

Numbers pooled deterministically across 20 published studies that passed our figure-accuracy checks — a quick synthesis, not a formal meta-analysis. Updated 7/17/2026.

Compounds compared by evidence

PubMed

How to read this: Ranked by the strength and volume of the evidence — NOT by how well a treatment works. A higher rank means a compound has been studied more, or in stronger study designs (e.g. randomized trials over lab studies), not that it produces better outcomes. The effect column shows the largest pooled figure reported, not a head-to-head comparison.

#CompoundEvidence strengthStudiesLargest pooled effect
1Carboplatin ChemotherapyHuman · observational2—
2Etoposide ChemotherapyHuman · observational2—
3Ifosfamide ChemotherapyHuman · observational2—

Ranked across 3 compounds with published studies for this cancer. Updated 7/17/2026.

Medicines & supplements studied for Intracranial Sarcoma

PubMedFDAClinicalTrials.gov

Every drug, supplement, and other agent the published studies cover for Intracranial Sarcoma, ranked by how strong the evidence is — what studies report, not a recommendation. Tap any to see its full profile.

Medicines · 3

CarboplatinHuman · observationalReported positive1 human

Human observational evidence only — no trials.

Largest credible effect: intratumoral_hemorrhage_among_hemisphere_cases 7, n=9 PMID 26588458 · effect sizes 2–14 across 9 studies

Most authoritative study: Successful treatment of primary intracranial sarcoma with the ICE chemotherapy regimen and focal radiation in children

Effect sizes reported in only 1 of 2 studies · All studies are small (n < 30).
ChemotherapyFDA off-label2 studiesFull profile →
EtoposideHuman · observationalReported positive1 human

Human observational evidence only — no trials.

Largest credible effect: intratumoral_hemorrhage_among_hemisphere_cases 7, n=9 PMID 26588458 · effect sizes 2–14 across 9 studies

Most authoritative study: Successful treatment of primary intracranial sarcoma with the ICE chemotherapy regimen and focal radiation in children

Effect sizes reported in only 1 of 2 studies · All studies are small (n < 30).
ChemotherapyFDA off-label2 studiesFull profile →
IfosfamideHuman · observationalReported positive1 human

Human observational evidence only — no trials.

Largest credible effect: intratumoral_hemorrhage_among_hemisphere_cases 7, n=9 PMID 26588458 · effect sizes 2–14 across 9 studies

Most authoritative study: Successful treatment of primary intracranial sarcoma with the ICE chemotherapy regimen and focal radiation in children

Effect sizes reported in only 1 of 2 studies · All studies are small (n < 30).
ChemotherapyFDA off-label2 studiesFull profile →

What recent studies report in Intracranial Sarcoma

These are reviewed studies whose abstracts concern Intracranial Sarcoma. Each describes only what that study reported. This is not a claim by OncoForge that any compound helps or harms Intracranial Sarcoma. Most are early lab, animal, or small human studies, and findings often conflict.

20 studies9 human⚠ Conflicting evidenceMechanism (15)Supportive care (1)

Tracking 20 published studies of Intracranial Sarcoma: 9 in humans, 11 reviews/other.

Reported direction across studies: 7 positive, 5 mixed, 8 inconclusive.

Findings conflict — both supportive and negative/mixed results exist (see below). Human evidence is limited.

These counts summarize what the studies reported; they are not a measure of whether anything works for Intracranial Sarcoma.

Compounds with studies mentioning Intracranial Sarcoma

Ifosfamide (2)Carboplatin (2)Etoposide (2)
ReviewMechanismInconclusiveLimited evidenceTier 4 · clinical

Mesenchymal Nonmeningothelial Tumors of the CNS: Evolving Molecular Landscape and Implications for Neuroradiologists

AJNR. American journal of neuroradiology · May 2025 · narrative review

mesenchymal nonmeningothelial tumors of the central nervous systemFET::CREB fusion-positive tumorsCIC-rearranged sarcomaprimary intracranial sarcoma, DICER1-mutantdural angioleiomyomaspindle cell neoplasm with NTRK rearrangement

This narrative review summarizes the WHO CNS5 updates to the classification and diagnostic criteria for mesenchymal nonmeningothelial CNS tumors and aligns CNS entities with soft-tissue tumor taxonomy. It highlights newly defined histomolecular entities (FET::CREB fusion-positive, CIC-rearranged sarcoma, and DICER1-mutant primary intracranial sarcoma), discusses emerging entities such as dural angioleiomyomas and NTRK-rearranged spindle cell tumors, and emphasizes that molecular techniques are essential for accurate diagnosis because histology and immunophenotype are often nonspecific.

Key findings
  • WHO CNS5 substantially revised terminology and diagnostic criteria for mesenchymal nonmeningothelial CNS tumors to better align with soft-tissue tumor classification.
  • The CNS chapter includes entities that occur exclusively or primarily in the CNS, most arising from the meninges and mainly located in the supratentorial compartment.
  • These tumors are grouped into soft tissue, chondro-osseous, and notochordal categories; soft tissue tumors are subdivided into fibroblastic, vascular, and skeletal muscle subtypes.
  • A new subcategory 'tumors of uncertain differentiation' includes three histomolecular entities: FET::CREB fusion-positive, CIC-rearranged sarcoma, and primary intracranial sarcoma, DICER1-mutant.
  • Emerging entities such as dural angioleiomyomas and spindle cell neoplasms with NTRK rearrangements are discussed though not included in WHO CNS5.
  • Because histology and immunophenotype are often nonspecific for tumors of uncertain differentiation, molecular techniques have become indispensable for accurate diagnosis.
Limitations: Narrative review without original, patient-level data reported in this article.; Not a primary research study; no new experimental results or pooled quantitative synthesis provided.; Scope and methods of literature selection are not detailed in the abstract (potential for incomplete coverage)..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Human · observationalMixed resultsLimited evidenceTier 3 · early humann = 25

Increase of primary intracranial sarcoma in children: Clinical manifestations, diagnosis, and management

Surgical neurology international · Nov 2024 · retrospective case series

primary intracranial sarcoma

This retrospective case series reviewed 25 children with primary intracranial sarcoma seen at a tertiary hospital in Peru from 2020–2023. Most presented with intracranial hypertension and radiologic hemorrhage; emergency craniotomy was common and gross total resection was achieved in 72% at first surgery. An adjuvant CTX-RT-CTX regimen was given to 72% of cases; among patients followed >1 year, those who started this regimen 2 weeks after gross total resection had survival >1 year compared with those who began complementary treatment after 4 weeks. The authors report an apparent increase in pediatric PIS incidence in recent years at their center.

Reported effects: cases_identified 25, n=25 · median_age 5, n=25 · +7 more

Key findings
  • Twenty-five pediatric PIS cases identified (study period Jan 2020–Dec 2023).
  • Median age was 5 years; slight female predominance (56%).
  • 68% presented with features of intracranial hypertension; radiologic cerebral hemorrhage was present in 80% of those with ICH and convulsion.
  • All but one case had a supratentorial tumor.
  • Emergency craniotomy was performed in 84% of cases; gross total resection (GTR) at first surgery achieved in 72% of cases.
  • An adjuvant chemoradiotherapy-chemotherapy (CTX-RT-CTX) regimen was used in 72% of cases; 12% started this regimen 2 weeks after surgical resection.
  • Cases followed >1 year that received CTX-RT-CTX after GTR had survival >1 year compared with cases that received complementary treatment after 4 weeks.
  • The authors state the incidence of pediatric PIS has increased in Peru in recent years.
Limitations: Retrospective, single-center case series.; Small sample size (n=25).; No randomized or contemporaneous control group for the timing of adjuvant therapy comparison.; Survival comparison by timing of adjuvant therapy is not quantified and may be confounded by selection and follow-up bias.; Follow-up duration is not fully reported for all cases.; No statistical testing or confidence intervals reported in the abstract..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Case reportMechanismInconclusiveLimited evidenceTier 3 · early humann = 1

Primary intracranial sarcoma, DICER-1 mutant, with hemorrhagic presentation: A case report

Surgical neurology international · Jul 2024 · case report

primary intracranial sarcoma

This is a single-patient case report of a 26-year-old man with a high-grade primary intracranial sarcoma found to have a DICER1-associated genomic profile. The tumor showed unusual hypervascularity with refractory hemorrhage and subdural effusions. Management included endovascular embolization, multiple surgeries, intrathecal etoposide, oral pazopanib, and adjuvant radiation; the abstract does not provide quantitative outcomes of these treatments.

Studied with: endovascular embolization, multiple surgical interventions, adjuvant radiation therapy.

Key findings
  • Patient had a high-grade spindle-celled neoplasm with sarcomatous features, multinucleated giant cells, and rare eosinophilic spheroids.
  • Genomic analysis identified the tumor as DICER1-associated primary intracranial sarcoma.
  • The case demonstrated anomalous hypervascularity, refractory hemorrhage, and subdural effusions as part of the presentation.
  • Therapies used included endovascular embolization, multiple surgical interventions, intrathecal etoposide injections, oral pazopanib, and adjuvant radiation therapy.
Limitations: Single-patient case report — findings may not generalize.; No control group or comparative data.; Abstract does not report quantitative outcomes or measures of treatment effectiveness.; Short/unclear follow-up and limited clinical outcome details in the abstract..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Human · observationalMechanismReported positiveLimited evidenceTier 3 · early humann = 8

Imaging Features of Primary Intracranial Sarcoma with DICER1 Mutation: A Multicenter Case Series

AJNR. American journal of neuroradiology · May 2024 · multicenter case series

primary intracranial sarcoma, DICER1-mutantCNS neoplasm

This multicenter case series described MRI and multimodality imaging features of primary intracranial sarcoma harboring DICER1 mutations in 8 patients. All 8 lesions showed blood products on T1-weighted imaging, and the 7 patients who had susceptibility-weighted imaging also demonstrated blood products. The authors note this tumor primarily affects pediatric and young adult patients and suggest that a cortical lesion with intralesional blood products on SWI and T1WI should raise consideration of this diagnosis.

Reported effects: blood_products_on_T1WI 8, n=8 · SWI_blood_products_observed 7, n=7

Key findings
  • Total of 8 patients with primary intracranial sarcoma, DICER1-mutant were included.
  • In all 8 patients, the lesion demonstrated blood products on T1-weighted imaging (T1WI).
  • Susceptibility-weighted imaging (SWI) was obtained in 7 patients and demonstrated blood products in those cases.
  • Primary intracranial sarcoma, DICER1-mutant primarily affects pediatric and young adult patients.
  • In younger patients, a cortical lesion with intralesional blood products on SWI and T1WI, with or without extra-axial blood products, should prompt inclusion of this entity in the differential diagnosis.
Limitations: Small sample size (n=8).; Case series design with no control or comparator group.; Descriptive imaging study without reported clinical outcomes or prospective validation.; Findings may have limited generalizability given rarity of the entity and small multicenter cohort..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

ReviewMechanismInconclusiveLimited evidenceTier 4 · clinical

Central nervous system tumors of uncertain differentiation

World neurosurgery: X · Feb 2024 · Literature review: search of PubMed and Google Scholar for terms including "uncertain differentiation", "Mesenchymal, non-meningothelial", "FET-CREB fusion positive", "DICER1-mutant sarcoma", and "CIC-Rearranged sarcoma"; selected articles were reviewed and summarized.

intracranial mesenchymal tumor, FET-CREB fusion-positiveCIC-rearranged sarcomaprimary intracranial sarcoma, DICER1-mutantcentral nervous system (CNS) tumors of uncertain differentiation

The authors performed a literature search and reviewed articles on CNS tumors of uncertain differentiation, including FET-CREB fusion-positive intracranial mesenchymal tumor, CIC-rearranged sarcoma, and DICER1-mutant primary intracranial sarcoma. The review summarizes diagnostic, prognostic, and therapeutic implications and notes that these entities have distinct molecular characteristics. Because these tumors have been described only recently, the authors report a lack of information about optimal treatment and prognosis.

Key findings
  • The 2021 WHO classification introduced a new subcategory: tumors of uncertain differentiation, which includes intracranial mesenchymal tumor (FET-CREB fusion-positive), CIC-rearranged sarcoma, and primary intracranial sarcoma, DICER1-mutant.
  • These tumors are mesenchymal, non-meningothelial, and have distinct molecular characteristics.
  • The review provides an update focused on diagnostic, prognostic, and therapeutic implications.
  • There is an important lack of information regarding the most appropriate treatment and prognosis for these recently described tumors.
Limitations: Narrative literature review with limited methodological detail provided in the abstract (not a described systematic review or meta-analysis).; No primary data or original experiments presented; conclusions are based on existing reports.; Entities are recently described, so the underlying evidence base is small and immature.; Abstract does not report search dates, inclusion/exclusion criteria, or quality assessment of included studies..

A concise review updating classification, molecular features, diagnostic and prognostic considerations, and therapeutic implications for newly defined CNS mesenchymal tumors.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Case reportReported positiveLimited evidenceTier 3 · early humann = 1

A Case of Primary Intracranial Sarcoma, DICER1-Mutant, in a Child with a Germline DICER1 Mutation

Brain sciences · Jul 2023 · case report

IfosfamideCarboplatinEtoposideprimary intracranial sarcoma, DICER1-mutant

This is a single-patient case report of a 10-year-old boy with a primary intracranial sarcoma harboring DICER1 mutations and a KRAS mutation. He underwent urgent surgical debulking followed by chemotherapy (ifosfamide, carboplatin, etoposide) and focal proton beam radiotherapy, after which the tumor showed a dramatic reduction and there was no radiographic evidence of residual disease at the primary site at the end of therapy.

Studied with: ifosfamide + carboplatin + etoposide chemotherapy, focal proton beam radiotherapy.

Key findings
  • Patient presented with a large right frontal hemorrhagic lesion; urgent debulking showed a high-grade sarcomatous lesion.
  • Molecular studies found compound heterozygous DICER1 variants (a frameshift insertion and a missense mutation) and a KRAS missense mutation; final diagnosis 'primary intracranial sarcoma, DICER1-mutant'.
  • Germline testing identified a germline DICER1 variant; parental testing was negative (variant thought most likely de novo).
  • Chemotherapy (ifosfamide, carboplatin, etoposide) combined with focal proton beam radiotherapy precipitated a dramatic reduction in tumor size and there was no evidence of residual disease at the primary site at the end of therapy.
Limitations: Single-patient case report (n=1), so findings are not generalizable.; No control or comparison group.; No dosing details or schedule for chemotherapy or radiotherapy provided in the abstract.; Follow-up duration and longer-term outcomes are not reported in the abstract..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Human · observationalMechanismReported positiveLimited evidenceTier 3 · early humann = 18

MRI findings of primary intracranial sarcomas in children

Pediatric radiology · Jul 2023 · cross-sectional descriptive observational study (review of cases diagnosed 2015–2021)

primary intracranial sarcoma

The authors reviewed MRI scans from 18 children (ages 1–18) with primary intracranial sarcomas diagnosed 2015–2021 to describe imaging characteristics. They report that these tumors were most often supratentorial and commonly showed contrast enhancement, diffusion restriction, hemorrhage, meningeal extension, and necrosis. The study is a descriptive observational series of a rare pediatric tumor.

Reported effects: contrast enhancement 100%, n=18 · diffusion restriction 78%, n=18 · +4 more

Key findings
  • Sample: 18 patients aged 1–18 years with primary intracranial sarcomas.
  • All tumors showed contrast enhancement (100%).
  • Diffusion restriction was present in 78% of cases.
  • Haemorrhage was present in 89% of cases.
  • Meningeal extension was present in 67% of cases.
  • Necrosis was present in 67% of cases.
  • Tumors were supratentorial in 72% of cases.
  • Authors conclude MRI findings are similar to other intracranial malignancies.
Limitations: Small sample size (18 patients).; Cross-sectional, descriptive observational design without a control or comparison group.; Limited generalizability due to rarity and small, likely single-cohort sample.; Retrospective case review (time window 2015–2021) which may be subject to selection bias..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

Case reportMechanismInconclusiveLimited evidenceTier 3 · early humann = 1

Intracranial mesenchymal tumor with (novel) COX14::PTEN rearrangement

Acta neuropathologica communications · Jun 2023 · case report

intracranial mesenchymal tumorprimary intracranial sarcomaMPNST-like sarcoma

This is a single-case report of a 43-year-old man with an intracranial mesenchymal tumor. Whole transcriptome sequencing of the tumor identified a novel COX14::PTEN gene rearrangement not previously reported. Methylation profiling did not match any established brain tumor methylation class but yielded a calibrated score of 0.89 for the 'Sarcoma, MPNST-like' class using a sarcoma classifier. The authors state further studies are needed to determine whether this represents a new entity.

Reported effect: calibrated score for 'Sarcoma, MPNST-like' by sarcoma classifier 0.89

Key findings
  • Single case of a 43-year-old man presenting with an intracranial mesenchymal tumor.
  • Histopathology showed a wide spectrum of peculiar morphological features and a non-specific immunohistochemical profile.
  • Whole transcriptome sequencing revealed a novel genetic rearrangement involving COX14 and PTEN genes (COX14::PTEN), not previously reported.
  • Methylation profiling: tumor did not cluster in any defined brain tumor methylation class; sarcoma classifier produced a calibrated score of 0.89 for 'Sarcoma, MPNST-like'.
Limitations: Single case report (n=1); findings may not be generalizable.; No functional studies or validation of the biological effect of the COX14::PTEN rearrangement were reported.; Tumor did not cluster with established brain tumor methylation classes, leaving classification uncertain.; No detailed clinical follow-up, treatment, or outcome data provided in the abstract..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Human · observationalMechanismMixed resultsLimited evidenceTier 3 · early humann = 14

Primary intracranial sarcomas: a clinicopathological investigation

Frontiers in oncology · Jun 2023 · retrospective case series

primary intracranial sarcoma

This retrospective case series analyzed 14 patients with primary intracranial sarcoma, reporting clinical, imaging, pathological features and targeted DNA sequencing in two cases. Chondrosarcoma was the most common histology; gross total resection (GTR) was performed in 9 patients and was associated with a trend toward better survival. Targeted NGS in two tumors identified mutations (e.g., NRAS, PIK3CA) and a SH3BP5::RAF1 fusion. Among 11 patients with follow-up, one developed lung metastases, three died, and eight were alive.

Reported effects: average_age 31.4, n=14 · headache_at_presentation 50%, n=14 · +13 more

Key findings
  • 14 PIS cases were retrospectively analyzed; average patient age was 31.4 years.
  • Chondrosarcoma was the most common histological type, followed by fibrosarcoma.
  • Twelve tumors were supratentorial and two were in the cerebellopontine angle.
  • Maximum tumor diameter ranged from 19.0&#xa0;mm to 130.0&#xa0;mm, with an average diameter of 50.3&#xa0;mm.
  • Eight of 10 MRI-scanned cases showed gadolinium enhancement (7 heterogeneous, 1 garland-like).
  • Targeted 481-gene NGS was performed in two cases and identified mutations including NRAS, PIK3CA, BAP1, KDR, BLM, PBRM1, TOP2A, DUSP2, CNV deletions of SMARCB1, and a SH3BP5::RAF1 fusion.
  • Nine patients underwent gross total resection (GTR) and five underwent subtotal resection; patients with GTR displayed a trend toward superior survival.
  • Among 11 patients with follow-up, one developed lung metastases, three died, and eight were alive.
Limitations: Small sample size (n=14) from a single retrospective series.; Targeted NGS was performed in only two cases, limiting genomic conclusions.; Follow-up data were incomplete (follow-up available for 11 of 14 patients) and no follow-up durations were reported.; Heterogeneous tumor histologies reduce ability to generalize findings to a single entity.; No control group or formal statistical analysis reported for survival comparisons..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Human · observationalMechanismReported positiveLimited evidenceTier 3 · early human

Genomic characterization of DICER1-associated neoplasms uncovers molecular classes

Nature communications · Mar 2023 · genomic/molecular classification study

DICER1-associated mesenchymal tumorssarcomaprimary intracranial sarcoma

The study performed genomic characterization of tumors associated with DICER1 syndrome and identified a group of mesenchymal tumors highly associated with the syndrome that are molecularly distinct from other DICER1-associated tumors. The authors propose three clinically meaningful molecular classes (LGMT DICER1, SARC DICER1, and PIS DICER1) and suggest a role for global hypomethylation and other recurrent molecular events in sarcomatous differentiation.

Key findings
  • Identified a group of mesenchymal tumors highly associated with DICER1 syndrome that are molecularly distinct from other DICER1-associated tumors.
  • This DICER1-associated mesenchymal tumor group includes multiple established clinicopathological tumor entities.
  • The group can be divided into three classes: low-grade mesenchymal tumor with DICER1 alteration (LGMT DICER1), sarcoma with DICER1 alteration (SARC DICER1), and primary intracranial sarcoma with DICER1 alteration (PIS DICER1).
  • The study suggests a role for global hypomethylation and other recurrent molecular events in sarcomatous differentiation of these tumors.
  • Authors state the classification could improve clinical management and facilitate future prognostication and therapeutic investigations.
Limitations: Abstract provides no sample size or detailed cohort description.; Observational molecular classification study; no interventional or outcome validation data reported in the abstract.; Role for global hypomethylation and other events is suggested but mechanistic/functional validation is not described in the abstract.; No mention of an independent validation cohort or clinical outcome correlations in the abstract..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Human · observationalMechanismReported positiveLimited evidenceTier 3 · early humann = 57

Some CNS sarcomas seen: A 22-year series

Clinical neuropathology · Mar 2023 · Retrospective case series (pathology database review, 2000–August 2022)

CNS/spinal sarcomaEwing sarcomaPEComaalveolar soft part sarcomaangiosarcomarhabdomyosarcomaCIC-rearranged sarcomaDICER1-mutant intracranial sarcomaintracranial mesenchymal tumor (FET::CREB fusion-positive)

The authors retrospectively reviewed pathology databases from 2000–August 2022 and identified 57 cases of primary or metastatic CNS/spinal sarcoma in adults and children. Ewing sarcoma was the most frequent diagnosis (n = 18). Only three cases required updating of their nomenclature according to CNS WHO 5th edition criteria. The authors report that almost all cases had been satisfactorily classified at the time of diagnosis using immunohistochemistry, FISH, or fusion testing.

Reported effects: total cases identified 57, n=57 · primary cases (adult vs pediatric) 16, n=57 · +5 more

Key findings
  • 57 cases were identified (total cohort).
  • There was a 16 : 15 primary and 19 : 7 metastatic ratio in adult versus pediatric patients, as reported.
  • Ewing sarcoma was the most frequent type (n = 18; 7 adult, 11 pediatric).
  • The cohort included a rare primary PEComa, 2 alveolar soft part sarcomas, and metastatic angiosarcoma.
  • Only 3 cases required nomenclature updating by CNS WHO5 criteria (an intracranial DICER-1 mutant sarcoma formerly diagnosed as rhabdomyosarcoma; an intracranial mesenchymal tumor, FET::CREB fusion-positive, formerly diagnosed as angiomatoid fibrous histiocytoma; and a CIC-rearranged sarcoma).
  • Almost all cases had been satisfactorily classified at the time of diagnosis using immunohistochemistry, FISH, or fusion results.
Limitations: Retrospective design based on pathology database text-word search (may miss cases).; Relies on diagnostic reports and tests performed at the time of original diagnosis rather than standardized re-testing.; Modest sample size (57 cases) over 22 years.; Data from referral hospital(s) — potential referral/selection bias; not population-based..

Useful for pathologists and clinicians interested in the frequency and molecular classification of CNS/spinal sarcomas and how many cases would be reclassified under WHO CNS5.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

ReviewMechanismInconclusiveModerate evidenceTier 4 · clinical

Mesenchymal non-meningothelial tumors of the central nervous system: a literature review and diagnostic update of novelties and emerging entities

Acta neuropathologica communications · Feb 2023 · literature review

central nervous system neoplasmsintracranial mesenchymal tumor, FET-CREB fusion-positiveCIC-rearranged sarcomaprimary intracranial sarcoma, DICER1-mutantrhabdomyosarcoma

This is a narrative literature review of mesenchymal, non-meningothelial tumors that occur in the central nervous system, summarizing changes in the WHO 5th edition classification. The authors describe newly recognized intracranial entities (including FET-CREB fusion-positive tumors, CIC-rearranged sarcomas, and DICER1-mutant primary intracranial sarcomas), discuss clinical presentation, radiology, histopathology, genetics and outcomes, and consider diagnostic strategies while introducing potentially novel tumor types.

Key findings
  • WHO 5th edition now includes mesenchymal tumors that occur uniquely or frequently in the CNS and aligns terminology with soft tissue counterparts.
  • New tumor types highlighted include 'intracranial mesenchymal tumor, FET-CREB fusion-positive', 'CIC-rearranged sarcoma', and 'Primary intracranial sarcoma, DICER1-mutant'.
  • Some entities (e.g., rhabdomyosarcoma) remain in the CNS classification because they may have CNS-specific features differing from soft-tissue counterparts.
  • The review covers clinical observations, radiology, histopathology, genetics, outcomes, and diagnostic strategies, and introduces some potentially novel tumor types.
Limitations: Narrative literature review with no new original patient-level data reported; Not described as a systematic review (possible selection or publication bias); Emerging entities discussed may have limited published outcome data.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Browse all studies mentioning Intracranial Sarcoma →

Where the evidence is

What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.

CompoundHuman evidenceMechanismSafetyTrial
Carboplatin11——
Etoposide11——
Ifosfamide11——

Study mix

20 published studies by what they were done in. Lab and animal findings often do not carry over to people.

9 Human11 Review/other
Reported directionReported positive7Mixed results5Inconclusive8

Compounds with reported-positive results in Intracranial Sarcoma

Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.

Human evidence

Ifosfamide2 positive1 human
Limitations: Single-patient case report (n=1), so findings are not generalizable.; No control or comparison group.; No dosing details or schedule for chemotherapy or radiotherapy provided in the abstract.; Follow-up duration and longer-term outcomes are not reported in the abstract.; Retrospective design; Very small sample size (final n = 8).
Cited positive studies (2)
Carboplatin2 positive1 human
Limitations: Single-patient case report (n=1), so findings are not generalizable.; No control or comparison group.; No dosing details or schedule for chemotherapy or radiotherapy provided in the abstract.; Follow-up duration and longer-term outcomes are not reported in the abstract.; Retrospective design; Very small sample size (final n = 8).
Cited positive studies (2)
Etoposide2 positive1 human
Limitations: Single-patient case report (n=1), so findings are not generalizable.; No control or comparison group.; No dosing details or schedule for chemotherapy or radiotherapy provided in the abstract.; Follow-up duration and longer-term outcomes are not reported in the abstract.; Retrospective design; Very small sample size (final n = 8).
Cited positive studies (2)

Evidence at a glance: compounds studied in Intracranial Sarcoma

A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.

CarboplatinHuman · observationalReported positive1 human

Human observational evidence only — no trials.

Largest credible effect: intratumoral_hemorrhage_among_hemisphere_cases 7, n=9 PMID 26588458 · effect sizes 2–14 across 9 studies

Most authoritative study: Successful treatment of primary intracranial sarcoma with the ICE chemotherapy regimen and focal radiation in children

Effect sizes reported in only 1 of 2 studies · All studies are small (n < 30).
EtoposideHuman · observationalReported positive1 human

Human observational evidence only — no trials.

Largest credible effect: intratumoral_hemorrhage_among_hemisphere_cases 7, n=9 PMID 26588458 · effect sizes 2–14 across 9 studies

Most authoritative study: Successful treatment of primary intracranial sarcoma with the ICE chemotherapy regimen and focal radiation in children

Effect sizes reported in only 1 of 2 studies · All studies are small (n < 30).
IfosfamideHuman · observationalReported positive1 human

Human observational evidence only — no trials.

Largest credible effect: intratumoral_hemorrhage_among_hemisphere_cases 7, n=9 PMID 26588458 · effect sizes 2–14 across 9 studies

Most authoritative study: Successful treatment of primary intracranial sarcoma with the ICE chemotherapy regimen and focal radiation in children

Effect sizes reported in only 1 of 2 studies · All studies are small (n < 30).

What the research shows for Intracranial Sarcoma

A plain-language summary of the reviewed studies OncoForge tracks for Intracranial Sarcoma. It reports what those studies described, not a claim that any compound or therapy helps or harms Intracranial Sarcoma. Most of this evidence is early, and findings often conflict.

  • A case series described three pediatric sarcoma patients (one ovarian sarcoma with germline DICER1 mutation; one metastatic peritoneal and one primary intracranial sarcoma with somatic DICER1 mutations).
  • The authors performed a literature review (including 83 previously reported cases) focused on DICER1-associated sarcomas and reported a recurring involvement of DICER1 alterations among a subset of sarcomas, including intracranial examples.
  • The evidence summarized is observational (case reports/series and literature review) and the analyses emphasized biomarker/mechanistic associations (DICER1 mutations) rather than testing treatments or interventions.

Supportive & alternative options discussed

  • Hyperthermia (heat): Also discussed as a supportive or adjunctive option in some brain-tumor care contexts, but not evaluated in the studies summarized here.
  • Exercise / prehabilitation: Also discussed as a supportive measure to maintain function and quality of life for people with intracranial tumors, but not addressed by the studies summarized here.
  • Mind–body (MBSR / CBT): Also discussed as a supportive approach (stress reduction, coping) for people with cancer, but not evaluated in these studies of intracranial sarcoma.
  • Acupuncture: Also discussed as a supportive option for symptom control in cancer care generally, but not studied in the reports summarized here.
  • Ketogenic / metabolic therapy: Also discussed by some as a complementary dietary approach in neuro-oncology, but not evaluated in these intracranial sarcoma studies.

What we don’t know yet

  • Whether DICER1 alterations are drivers of intracranial sarcoma biology or incidental findings in some tumors is not established.
  • The prevalence of DICER1 mutations among all intracranial sarcomas and their prognostic significance remain unclear.
  • There are no clinical trials reported here testing therapies targeted to DICER1-mutant tumors or showing how DICER1 status should change patient management.
  • Optimal testing approaches, timing, and implications for genetic counseling (germline vs somatic findings) are not resolved by these reports.
These findings are preliminary and based on small case series and a literature review; they describe an association between DICER1 alterations and some sarcomas (including intracranial cases) but do not establish clinical utility or therapeutic implications.

Clinical trials in Intracranial Sarcoma

1 ongoing · 1 completed · tracked from ClinicalTrials.gov. Recruiting is not the same as proven, and completed is not the same as positive — read the results. Not a recommendation.

Completed
2 stopped (terminated / withdrawn / suspended)

Search all trials on ClinicalTrials.gov →

Getting care & support

Nonprofit / Gov

Practical, vetted help for Intracranial Sarcoma — advocacy, paying for treatment, second opinions, and caregivers.

If you’re struggling emotionally, you don’t have to wait.

Advocacy & community

No dedicated organization for this specific cancer is curated yet — these general organizations can help in the meantime.

Financial help

  • PAN Foundation ↗ — Copay assistance funds by diagnosis (funds open and close as money allows). · status changes often — check the fund’s site
  • HealthWell Foundation ↗ — Copay and premium assistance funds by disease. · status changes often — check the fund’s site
  • CancerCare — financial assistance ↗ — Limited grants plus free financial counseling. · status changes often — check the fund’s site
  • Family Reach ↗ — Help with everyday living costs (rent, transport, food) during treatment. · status changes often — check the fund’s site
  • NeedyMeds ↗ — Searchable directory of drug patient-assistance and discount programs. · status changes often — check the fund’s site
What you’ll typically need to apply
  • Your diagnosis and, if you have it, the specific drug/treatment name (from your care team).
  • Insurance details — your member ID card, or a note that you're uninsured (some funds require active insurance, some don't).
  • Proof of income and household size (recent pay stubs, a tax return, or a benefits letter) — most funds are income-based.
  • Your prescriber's contact information; some programs need the clinic to submit part of the application.
  • Apply early and re-check: funds open and close as money is available, so a closed fund may reopen.

General guidance — each program sets its own eligibility. Confirm requirements on the program’s site.

Help paying for the medicines on this page

Second opinions

Caregiver support

We list only non-profit and government resources — never product sellers — and take no affiliate fees. If a link is broken or a resource doesn't meet that bar, tell us.

Heading to an appointment? Get a printable one-page summary — studied compounds, open trials, interactions, and questions to ask.
Bring this to your appointment →